Imatinib, an inhibitor of several tyrosine kinases, including BCR-ABL, c-KIT, and PDGF-Rs, significantly mitigated PDGF-induced breast cancer cell proliferation, invasiveness, and migratory capacity, associated with downregulation of SDC2 and 4 expressions [158,179]. Here, SDC2 is linked to breast carcinoma.